{"title":"Surgery versus radiotherapy for older patients (aged≥65 years) with stage I-II laryngeal cancer: an investigational study from the SEER database.","authors":"Wangyan Zhong, Xueying Jin, Ting Li, Jiwei Mao, Hang Yuan, Jiangfeng Feng","doi":"10.1080/14737140.2025.2458159","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Currently, the choice between radiotherapy and surgery for treating older patients with early laryngeal cancer remains unclear. The aim of this retrospective study is to investigate the therapeutic patterns and survival outcomes for a cohort of older patients with early laryngeal cancer who received radiation therapy (RT) or surgery.</p><p><strong>Methods: </strong>Clinical records of 1833 patients aged 65+ with stage I/II laryngeal cancer from the SEER registry (2010-2015) were assessed. Of these, 1319 underwent RT and 514 had surgery alone. Kaplan-Meier analysis assessed overall survival (OS) and cancer-specific survival (CSS), with Log-rank tests for comparison.</p><p><strong>Results: </strong>The 5-year OS and CSS rates were 61.1% and 80.6%, respectively. Univariate analysis showed age, gender, T stage, histology, and treatment as prognostic factors for OS and CSS. Multivariate analysis linked age, T stage, and treatment to OS, and gender, histology, T stage, and treatment to CSS. Surgery improved OS and CSS for most early-stage patients, except those with grade III cancer.</p><p><strong>Conclusion: </strong>Among early-stage laryngeal cancer patients aged 65 years or older reported in the SEER database, those treated with surgery experienced longer OS and CSS compared to those treated with RT, except for patients with grade III.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"181-187"},"PeriodicalIF":2.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2025.2458159","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Currently, the choice between radiotherapy and surgery for treating older patients with early laryngeal cancer remains unclear. The aim of this retrospective study is to investigate the therapeutic patterns and survival outcomes for a cohort of older patients with early laryngeal cancer who received radiation therapy (RT) or surgery.
Methods: Clinical records of 1833 patients aged 65+ with stage I/II laryngeal cancer from the SEER registry (2010-2015) were assessed. Of these, 1319 underwent RT and 514 had surgery alone. Kaplan-Meier analysis assessed overall survival (OS) and cancer-specific survival (CSS), with Log-rank tests for comparison.
Results: The 5-year OS and CSS rates were 61.1% and 80.6%, respectively. Univariate analysis showed age, gender, T stage, histology, and treatment as prognostic factors for OS and CSS. Multivariate analysis linked age, T stage, and treatment to OS, and gender, histology, T stage, and treatment to CSS. Surgery improved OS and CSS for most early-stage patients, except those with grade III cancer.
Conclusion: Among early-stage laryngeal cancer patients aged 65 years or older reported in the SEER database, those treated with surgery experienced longer OS and CSS compared to those treated with RT, except for patients with grade III.
期刊介绍:
Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches.
Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care.
Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections:
Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results
Article Highlights – an executive summary of the author’s most critical points.